Hemanext ONE is the first meaningful FDA-authorized processing and storage technology proven to mitigate the red blood cell (RBC) storage lesion.1-4
Transforming Red Blood Cells 
Advancing Care.TM
Hemanext is a global biomedical technology pioneer in transfusion medicine. We recognize the vital role of blood for patients and are committed to optimizing its therapeutic impact and value to the healthcare system. Focused on the study of hypoxically stored RBCs, our research and development efforts aim to significantly improve the quality of stored RBCs worldwide. We strive to achieve our mission of delivering innovations that improve the standard of care for patients who rely on transfusions by transforming RBCs through protecting their quality, functionality, and viability during storage.
Latest News and Events
Hemanext Announces Close of Series B-2 Equity Funding Round
LEXINGTON, Mass., January 27, 2025, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces close of series B-2 equity fundraising round. The B-2 fundraising was launched in May 2024 to raise $16-20 million...
Hemanext Inc. Announces First Patients Treated In A Clinical Trial Investigating the Efficacy of the Hemanext ONE® Red Blood Cell Processing and Storage System
LEXINGTON, Mass., December 20, 2024, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces that the first two patients enrolled have begun receiving transfusions in a multi-center, randomized, controlled cross-over...
Hemanext signs agreement with Hemara Bio, a healthcare distributor in the U.A.E., to provide hospitals and clinicians across the GCC Region with Hemanext ONE® system
LEXINGTON, Mass., October 29, 2024, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announced that it has entered into an exclusive distribution agreement with Hemara Bio in Dubai, United Arab Emirates (UAE)...
Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.”
Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.” LEXINGTON, Mass., September 9, 2024, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a...
Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study
Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study, a Significant Milestone for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System LEXINGTON, Mass., August 20, 2024, – Hemanext Inc., a leading innovator...
Hemanext Research
Learn more about Hemanext and take a closer look at our publications, studies, and posters focused on blood quality and red blood cell characterization.